A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma [clinicaltrials:NCT01455493]

Bio2RDF uri

A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma [clinicaltrials:NCT01455493]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT01455493

Bio2RDF identifier

NCT01455493

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01455493

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

This is a multicenter, ...... -0980 will also be evaluated.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Objective tumor response as assessed by the investigator using RECIST v1.1 up to approximately 23 months [clinicaltrials_resource:443f0cec490bc9396e219ab9f4de11e8]

Objective tumor response as assessed by the investigator using RECIST v1.1 up to approximately 23 months [clinicaltrials_resource:dca22d0b51f40effaaf13004b579f75c]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Objective tumor response as assessed by the investigator using RECIST v1.1 up to approximately 23 months [clinicaltrials_resource:002d4645f7ed7972d47f61c81fa10464]

Objective tumor response as assessed by the investigator using RECIST v1.1 up to approximately 23 months [clinicaltrials_resource:1e540844eb2d6a86bfd9c28e9b56bbbd]

Objective tumor response as assessed by the investigator using RECIST v1.1 up to approximately 23 months [clinicaltrials_resource:ac8027b2dd684e2b48f90bedd7b7c726]

Objective tumor response as assessed by the investigator using RECIST v1.1 up to approximately 23 months [clinicaltrials_resource:d4ee02e6ef87cd6e267f4c6e17a5c4cc]

Objective tumor response as assessed by the investigator using RECIST v1.1 up to approximately 23 months [clinicaltrials_resource:f0ea730917d500f3a50866f7ae65d550]

completion date [clinicaltrials_vocabulary:completion-date]

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Endometrial Carcinoma [clinicaltrials_resource:238376fc1a3f33fdb69eac725ba218c6]

condition browse [clinicaltrials_vocabulary:condition-browse]

Carcinoma [clinicaltrials_resource:506566f9cdd0caf88175444976503e1f]

Endometrial Neoplasms [clinicaltrials_resource:5782f389fa98f8e76c4a4bf5389996d1]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Carcinoma [clinicaltrials_resource:506566f9cdd0caf88175444976503e1f]

Endometrial Neoplasms [clinicaltrials_resource:5782f389fa98f8e76c4a4bf5389996d1]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01455493 [clinicaltrials_resource:b7cf54fea2f7e6f1b89136f2d24e3729]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2011-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

GDC-0980 [clinicaltrials_resource:7e42cd482d54d0f066b3ba88a12265f8]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Genentech, Inc. [clinicaltrials_resource:4f45531bd1684a221716f54db60ca150]

location [clinicaltrials_vocabulary:location]

[clinicaltrials_resource:cb5c82c73a96d079b6b05bb26708c351]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01455493

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Multicenter, Single-Arm, Ope ...... rsistent Endometrial Carcinoma

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

PIM4972g

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Clinical Trials [clinicaltrials_resource:6ba74fbb1e833f8c8b13bcf9634cf25f]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Genentech, Inc. [clinicaltrials_resource:4f45531bd1684a221716f54db60ca150]

start date [clinicaltrials_vocabulary:start-date]

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01455493 study design [clinicaltrials_resource:fc4ac05efe9010562d0f170cf6ab7e2a]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01455493

verification date [clinicaltrials_vocabulary:verification-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01455493

http://www.w3.org/2001/XMLSchema#string

title

A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

A Study of GDC-0980 in the Tre ...... a [clinicaltrials:NCT01455493]

@en